These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 3982566

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
    Melamed E.
    Adv Neurol; 1990; 53():61-6. PubMed ID: 2173376
    [No Abstract] [Full Text] [Related]

  • 4. Dopamine agonists and Parkinson's disease.
    Burton K, Calne DB.
    Clin Neurol Neurosurg; 1984; 86(3):172-7. PubMed ID: 6091965
    [Abstract] [Full Text] [Related]

  • 5. Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?
    Carlsson A.
    J Neural Transm Suppl; 1983; 19():153-61. PubMed ID: 6321646
    [Abstract] [Full Text] [Related]

  • 6. [Medicinal treatment of idiopathic Parkinson's disease].
    Klockgether T.
    Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
    [Abstract] [Full Text] [Related]

  • 7. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
    Hornykiewicz O.
    Neurodegener Dis; 2008 Mar; 5(3-4):114-7. PubMed ID: 18322366
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Dopaminergic agonists in Parkinson disease].
    Dubois B, Agid Y.
    Rev Prat; 1986 Jan 21; 36(5):207-14. PubMed ID: 3961400
    [No Abstract] [Full Text] [Related]

  • 12. [Current views on the pathogenesis and pharmacotherapy of Parkinson disease].
    Kostowski W.
    Neurol Neurochir Pol; 1987 Jan 21; 21(6):541-7. PubMed ID: 2835696
    [No Abstract] [Full Text] [Related]

  • 13. Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity.
    Knoll J.
    Adv Neurol; 1990 Jan 21; 53():425-9. PubMed ID: 2122648
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Drug therapy in Parkinson's disease].
    van Hilten JJ, Roos RA.
    Ned Tijdschr Geneeskd; 1999 Jan 30; 143(5):234-40. PubMed ID: 10086151
    [Abstract] [Full Text] [Related]

  • 16. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what.
    Metman LV, Konitsiotis S, Chase TN.
    Mov Disord; 2000 Jan 30; 15(1):3-8. PubMed ID: 10634235
    [No Abstract] [Full Text] [Related]

  • 17. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P, Parkinson-Control Study Group.
    Mov Disord; 2006 Apr 30; 21(4):500-9. PubMed ID: 16267842
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
    Yokochi M.
    Parkinsonism Relat Disord; 2009 Jan 30; 15 Suppl 1():S25-30. PubMed ID: 19131038
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.